1. Ontario study: SGLT2 inhibitor use linked to reduced risk of hyperkalemia in older adults already on RAAS therapy.
2. Over 39,000 adults aged 66 and older with diabetes, heart failure, or chronic kidney disease were included.
3. SGLT2i users had lower incidence of hyperkalemia and fewer hospital encounters for hyperkalemia.
4. SGLT2i users were more likely to continue their RAAS therapy.
5. Protective effects of SGLT2i on kidney and cardiovascular health highlighted.
6. The study concluded that SGLT2i introduction may help overcome obstacles to optimal therapy in patients with diabetes, CKD, and heart failure.
7. Empagliflozin was the most commonly prescribed SGLT2 inhibitor.

Source: JAMA Internal Medicine